Why the study?
Does DELFIA using recombinant VP6 proteins accurately measure anti-rotavirus immune responses compared to ELISA in children?
Does DELFIA using recombinant VP6 proteins accurately measure anti-rotavirus immune responses compared to ELISA in children?
Recombinant VP6 proteins can be used in a DELFIA assay to accurately measure anti-rotavirus immune responses, performing comparably to standard ELISA.
May support DELFIA as an ELISA alternative for pediatric rotavirus serology; hypothesis-generating and requires prospective validation before adoption.
The rotavirus (RV) inner capsid protein VP6 is widely used to evaluate immune response during natural infection and in vaccine studies. Recombinant VP6 from the most prevalent circulating rotavirus strains in each subgroup (SG) identified in a birth cohort of children in southern India [SGII (G1P[8]) and SGI (G10P[11])] were produced. The purified proteins were used to measure VP6-specific antibodies in a Dissociation-Enhanced Lanthanide Fluorometric Immunoassay (DELFIA). The ability of the assay to detect a ≥2 fold rise in IgG level in a panel of serum samples from a longitudinal study was compared to a gold standard virus-capture ELISA. A strong association was observed between the assays (p<0.001; chi-squared test) with assay performances remaining similar when the samples were subdivided as having a fold change increase in VP6 antibody levels (a) within 90 days of RV RNA detection in stool or (b) if no RV RNA was detected within that time period. This study demonstrates the suitability of using recombinant proteins to measure anti-RV immune responses and serves as a "proof of principle" to examine the antibody responses generated to other recombinant RV proteins and thereby possibly identify a correlate of protection.
No takes yet. Share an insight, caveat, or question.
Kavanagh et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: